The winged helix (WH) proteins form a growing family of transcriptional regulators that share a conserved DNA binding domain. These proteins function as developmental switches. They determine tissue and organ differentiation in vertebrate and invertebrate animals. WH proteins have oncogenic potential; gain of function mutations in these proteins act in a dominant fashion to cause cancer in animals (avian sarcomas) and humans (alveolar rhabdomyosarcoma and acute lymphoblastic leukemia). The goal of the proposed research is an understanding of the molecular mechanisms that operate in WH oncogenesis. The proteins to be studied are Qin, a telencephalon-specific protein that is also expressed as the oncogenic determinant in a retrovirus, CWH2, a mutant form of the chicken homolog of mesenchyme forkhead protein, and the human fusion proteins PAX3-FKHR and PAX7-FKHR, the putative causes of alveolar rhabdomyosarcoma. Mutations that activate the oncogenic potential of WH proteins will be defined, and their effects on DNA binding and transcriptional regulation will be determined. Interactions between WH proteins and the transcription preinitiation complex will be studied, and the participation of coregulators in this interaction will be tested. Finally, downstream targets of WH proteins will be identified and isolated, and their roles in the transformation process will be determined. Aberrant transcriptional regulation lies at the heart of oncogenesis. The nature of activating mutations, the interactions with the preinitiation complex, and the identity and function of target genes will reveal novel molecular targets for therapeutic intervention.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA079616-05
Application #
6633271
Study Section
Cellular Biology and Physiology Subcommittee 1 (CBY)
Program Officer
Cole, John S
Project Start
1999-09-01
Project End
2005-06-30
Budget Start
2003-07-01
Budget End
2005-06-30
Support Year
5
Fiscal Year
2003
Total Cost
$299,551
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
781613492
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Harada, Josephine N; Bower, Kristen E; Orth, Anthony P et al. (2005) Identification of novel mammalian growth regulatory factors by genome-scale quantitative image analysis. Genome Res 15:1136-44
Iacovoni, Jason S; Cohen, Steven B; Berg, Thorsten et al. (2004) v-Jun targets showing an expression pattern that correlates with the transformed cellular phenotype. Oncogene 23:5703-6
Miura, Yutaka; Kainuma, Mami; Jiang, Hao et al. (2004) Reversion of the Jun-induced oncogenic phenotype by enhanced synthesis of sialosyllactosylceramide (GM3 ganglioside). Proc Natl Acad Sci U S A 101:16204-9
Bader, Andreas G; Felts, Katherine A; Jiang, Ning et al. (2003) Y box-binding protein 1 induces resistance to oncogenic transformation by the phosphatidylinositol 3-kinase pathway. Proc Natl Acad Sci U S A 100:12384-9
Nishizawa, Makoto; Fu, Shu-Ling; Kataoka, Kohsuke et al. (2003) Artificial oncoproteins: modified versions of the yeast bZip protein GCN4 induce cellular transformation. Oncogene 22:7931-41
Iacovoni, Jason S (2003) GeneHuggers: database mining and application connectivity tools for subsequence analyses of the human genome. Bioinformatics 19:2316-8
Ahlgren, Sara; Vogt, Peter; Bronner-Fraser, Marianne (2003) Excess FoxG1 causes overgrowth of the neural tube. J Neurobiol 57:337-49
Nishizawa, Makoto; Kataoka, Kohsuke; Vogt, Peter K (2003) MafA has strong cell transforming ability but is a weak transactivator. Oncogene 22:7882-90
Aoki, Masahiro; Sobek, Vera; Maslyar, Daniel J et al. (2002) Oncogenic transformation by beta-catenin: deletion analysis and characterization of selected target genes. Oncogene 21:6983-91
Aoki, M; Blazek, E; Vogt, P K (2001) A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci U S A 98:136-41

Showing the most recent 10 out of 13 publications